Chronic heart failure with cognitive impairment
Conditions
Interventions
Experimental Group:Qiliqiangxin capsule + conventional medicine treatment
Sponsors
Dongzhimen Hospital of Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria of heart failure aged 50-80 years old male or female; 2) patients with onset time =3 months cardiac function II-III; 3) patients with stable clinical manifestations clear consciousness able to communicate with language understand the survey content and can answer relevant questions; 4) meet the diagnostic criteria of mild cognitive impairment; 5) Informed consent voluntary test and signed informed consent. 6) NT-proBNP > 450ng/L; 7) Heart failure meets the diagnostic criteria of Yang qi deficiency and blood stasis syndrome of TCM syndrome differentiation.
Exclusion criteria
Exclusion criteria: 1) Chronic heart failure is caused by heart valve disease congenital heart disease pericardial disease arrhythmia or other non-cardiac causes; 2) patients scheduled for coronary revascularization at 12 weeks; Patients with unrepaired primary valvular heart disease left ventricular outflow tract obstruction aneurysm uncontrolled severe arrhythmia cardiogenic shock unstable angina or acute myocardial infarction; Patients with uncontrolled blood pressure; 3) severe cerebrovascular diseases such as cerebral infarction cerebral hemorrhage etc.; 4) patients with other diseases that can cause cognitive impairment such as disturbance of consciousness epilepsy intracranial infection tumor head trauma poisoning metabolic diseases alcoholism etc.; (5) patients with severe primary diseases of liver kidney hematopoietic system endocrine system respiratory system and severe liver and kidney function damage; 6) patients with acute infectious diseases pregnant or lactating women patients with severe mental diseases allergic constitution and allergic to multiple drugs. 7) Patients who participated in other drug clinical trials in the past one month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MoCA score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Transthoracic echocardiography related indicators;Plasma neuron-derived exosome differential proteins;6-minute walk test distance;NYHA cardiac function classification;The score of TCM syndrome element assessment scale;Plasma NT-proBNP level; | — |
Countries
China
Contacts
Public ContactLei Wang
Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital
Outcome results
None listed